Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (Nasdaq: RXRX) will report fourth quarter and full year 2025 business updates and financial results on Wednesday, February 25, 2026, before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube accounts, and investors may submit questions in advance via the company’s online form.
Recursion (NASDAQ: RXRX) announced that on February 6, 2026 its Compensation Committee approved inducement restricted stock unit awards covering 820,431 shares of Class A common stock granted to 17 new employees under the 2024 Inducement Equity Incentive Plan.
Each RSU vests 25% at the first quarterly vesting date on or after the one-year anniversary of the vesting commencement date, then vests at 1/16th each quarter thereafter, subject to continued employment and plan/grant agreement terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).
Recursion (Nasdaq: RXRX) announced that CEO & President Najat Khan, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30am PT in San Francisco.
Management will also participate in the 28th Annual Needham Growth Conference on Friday, January 16, 2026. Webcasts will be available in the events section of Recursion Investor Relations at ir.recursion.com.
Recursion (NASDAQ: RXRX) reported positive Phase 1b/2 TUPELO results for REC-4881 in familial adenomatous polyposis (FAP) on Dec 8, 2025. REC-4881 (4 mg QD) produced a 43% median polyp-burden reduction at 12 weeks (n=12) with 75% of evaluable patients showing reductions. At Week 25—12 weeks after stopping therapy—82% (9 of 11) maintained reductions with a 53% median decrease from baseline. Safety was consistent with MEK1/2 inhibition: mostly Grade 1–2 TRAEs, 15.8% Grade 3, and no Grade ≥4 reported. Natural-history data showed 87% of similar untreated FAP patients had annualized polyp increases (n=55). Next steps include FDA engagement in 1H26 and population/dosing expansion.
Recursion (Nasdaq: RXRX) will host a webinar on December 8, 2025 to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP).
The live webinar is scheduled for 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT and will stream on Recursion's X, LinkedIn, and YouTube channels. The session is titled: Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy.
Presenters include Najat Khan, Ph.D. (incoming CEO and President), David Mauro, M.D., Ph.D., Beth Bruckheimer, Ph.D., Jessica Stout, D.O., and Alfred Cohen, M.D.
Recursion (Nasdaq: RXRX) reported Q3 2025 results and a business update on Nov 5, 2025, highlighting a $30 million milestone from Roche/Genentech for a microglia whole-genome phenomap and surpassing $500 million in cumulative partner upfronts and milestones. Cash and cash equivalents were $667.1M as of Sept 30, 2025 and approximately $785M as of Oct 9, 2025 (unaudited), with an expected runway through end of 2027 absent additional financing. Q3 revenue was $5.2M vs $26.1M year-ago; R&D expenses were $121.1M; net loss was $162.3M. Pipeline progress included REC-617 dose escalation, REC-7735 nominated as a development candidate, and REC-4881 data due Dec 2025.
Recursion (NASDAQ: RXRX) announced a Board‑approved leadership transition effective January 1, 2026. Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and Board member, will become CEO and President while remaining on the Board. Co‑founder Chris Gibson, Ph.D. will transition from CEO to Chairman of the Board. Rob Hershberg, MD/Ph.D., current Chairman, will become Vice‑Chairman and Lead Independent Director. The Board cited continuity and execution as goals for advancing the OS platform, pipeline readouts, and commercialization priorities.
Recursion (Nasdaq: RXRX) announced participation in two upcoming investor conferences in November 2025. The company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and at the Jefferies Global Healthcare Conference London on Tuesday, November 18, 2025. Webcasts will be available in the events section of Recursion's investor relations website at ir.recursion.com.
Recursion (Nasdaq: RXRX) will report third quarter 2025 business updates and financial results on Wednesday, November 5, 2025 before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube channels. Investors, analysts, and the public can submit questions in advance via the company’s online form at the provided link.
Recursion (NASDAQ:RXRX), a clinical stage TechBio company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Citi 2025 BioPharma Back to School Conference on September 3 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Investors can access the webcasts through Recursion's investor relations website at ir.recursion.com.